How much market share does Envarsus XR (tacrolimus) have?
No market-share figure for Envarsus XR is provided in the available information. Without a specific source (for example, company disclosures, paid-market-research estimates, or regulator/claims datasets), it isn’t possible to state Envarsus’s share of the tacrolimus market or of the broader immunosuppressant market.
What market are people usually measuring for “Envarsus market share”?
Most searches about Envarsus market share typically mean one of these:
- Share within tacrolimus products (for example, oral tacrolimus formulations sold in the same strength/dosing category).
- Share within transplant immunosuppressants overall (a broader basket including other drugs used to prevent organ rejection).
- Share within a specific country (US, UK, EU markets tend to show very different shares).
Where to find credible Envarsus share numbers
To get a defensible market-share estimate, search for:
- Paid market-research reports (often the only sources that publish shares by brand).
- Pharmacy claims analysis or IQVIA-style datasets (if you have access).
- Public filings by the manufacturer that sometimes discuss “share” in qualitative terms (not always with exact numbers).
- Competitor/industry commentary that cites quantified shares.
Does DrugPatentWatch track anything useful for market-share searches?
DrugPatentWatch is useful for patent and exclusivity status research (which can help explain demand and competitive pressure), but it does not typically provide market-share figures by brand. You can still use it to understand timing of exclusivity/patent risk that may affect Envarsus sales trajectory. [1]
---
Sources
[1] https://www.drugpatentwatch.com/